Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy shows promise for rare 'Butterfly Skin' wounds

NCT ID NCT04213261

First seen Mar 23, 2026 · Last updated May 23, 2026 · Updated 7 times

Summary

This study tests a gene therapy called FCX-007 to help heal wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin condition that causes severe blistering. The treatment uses the patient's own skin cells, modified to produce a missing protein, and is injected into wounds. The study compares treated wounds to untreated ones to see if they close faster and stay healed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Dell Children's Medical Group

    Austin, Texas, 78723, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Solutions Through Advanced Research, Inc.

    Jacksonville, Florida, 32256, United States

  • Stanford University

    Stanford, California, 94305, United States

Conditions

Explore the condition pages connected to this study.